Farallon Capital Management Llc Buys T-Mobile US Inc, Aon PLC, 58.com Inc, Sells IAC/InterActiveCorp, Cigna Corp, Fidelity National Information Services Inc

• New Purchases: TMUS, AON, WUBA, BMY, NYT, CZR, CZR, CZR, EDU, ARNA, ZNTL, LNTH, PTLA, TGTX, AMRS, PLRX, ADAP, RCUS, HWM, LQDA, RPRX, CNST, ATTO, ARYBU, RPTX, AKUS, FUSN, ISEE, DMTK, CTMX, RNA,
• Added Positions: BX, FB, MYOK, SRPT, IOVA, CYTK, PTGX, FATE, CHTR, ABBV, FSCT, APLS, IQV, KRYS, V, SAGE, MRTX, EXEL, QURE, KRTX, FGEN, RC, RDUS,
• Reduced Positions: CI, FIS, GD, WAB, GOOG, INFO, TRU, ALNY, TMO, MSFT, ZYME, BABA, SHW, ASND, PANW, NVTA, EFX, CNC, VCYT, CRM, TCDA, DCPH, EQIX, ZEAL, CRSP, XLRN, ARWR, ZGNX, PRNB, AKBA, QGEN, AMRN, AVRO, SVRA, UTHR,
• Sold Out: IAC, FTSV, RARX, PGNX, MNTA, ATRA, STML, QTNT, VSTM, ADSW, OPTN, XRX, AGTC, EIGR, PHAS,

For the details of FARALLON CAPITAL MANAGEMENT LLC's stock buys and sells, go to https://www.gurufocus.com/guru/farallon+capital+management+llc/current-portfolio/portfolio

1. IQVIA Holdings Inc (IQV) - 3,796,030 shares, 4.76% of the total portfolio. Shares added by 1.51%
2. Fidelity National Information Services Inc (FIS) - 3,590,128 shares, 4.25% of the total portfolio. Shares reduced by 22.31%
3. Centene Corp (CNC) - 7,000,000 shares, 3.93% of the total portfolio. Shares reduced by 3.45%
4. AbbVie Inc (ABBV) - 4,150,000 shares, 3.60% of the total portfolio. Shares added by 3.75%
5. Thermo Fisher Scientific Inc (TMO) - 1,069,505 shares, 3.42% of the total portfolio. Shares reduced by 13.97%

Farallon Capital Management Llc initiated holding in T-Mobile US Inc. The purchase prices were between $81.98 and $110.19, with an estimated average price of $95.53. The stock is now traded at around $116.02. The impact to a portfolio due to this purchase was 3.18%. The holding were 3,457,631 shares as of .

Farallon Capital Management Llc initiated holding in Aon PLC. The purchase prices were between $153.68 and $200.2, with an estimated average price of $186.19. The stock is now traded at around $196.42. The impact to a portfolio due to this purchase was 2.93%. The holding were 1,720,498 shares as of .

Farallon Capital Management Llc initiated holding in 58.com Inc. The purchase prices were between $46.7 and $54.58, with an estimated average price of $51.49. The stock is now traded at around $55.69. The impact to a portfolio due to this purchase was 2.37%. The holding were 4,965,212 shares as of .

Farallon Capital Management Llc initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $54.82 and $64.09, with an estimated average price of $59.75. The stock is now traded at around $63.03. The impact to a portfolio due to this purchase was 1.88%. The holding were 3,625,000 shares as of .

Farallon Capital Management Llc initiated holding in New York Times Co. The purchase prices were between $28.44 and $42.78, with an estimated average price of $36.23. The stock is now traded at around $43.99. The impact to a portfolio due to this purchase was 1.54%. The holding were 4,137,542 shares as of .

Farallon Capital Management Llc initiated holding in Cronus Resources Ltd. The purchase prices were between $6.28 and $12.45, with an estimated average price of $10.03. The stock is now traded at around $0.00. The impact to a portfolio due to this purchase was 0.86%. The holding were 8,015,000 shares as of .

Farallon Capital Management Llc added to a holding in Blackstone Group Inc by 587.25%. The purchase prices were between $40.8 and $59.45, with an estimated average price of $52.49. The stock is now traded at around $53.56. The impact to a portfolio due to this purchase was 1.19%. The holding were 2,768,319 shares as of .

Farallon Capital Management Llc added to a holding in Facebook Inc by 24.92%. The purchase prices were between $154.18 and $242.24, with an estimated average price of $208.03. The stock is now traded at around $262.34. The impact to a portfolio due to this purchase was 0.54%. The holding were 1,358,494 shares as of .

Farallon Capital Management Llc added to a holding in MyoKardia Inc by 103.49%. The purchase prices were between $44.2 and $121.69, with an estimated average price of $82.77. The stock is now traded at around $101.14. The impact to a portfolio due to this purchase was 0.38%. The holding were 875,000 shares as of .

Farallon Capital Management Llc added to a holding in Sarepta Therapeutics Inc by 50.00%. The purchase prices were between $93 and $171.7, with an estimated average price of $135.31. The stock is now traded at around $159.04. The impact to a portfolio due to this purchase was 0.25%. The holding were 525,000 shares as of .

Farallon Capital Management Llc added to a holding in Cytokinetics Inc by 140.00%. The purchase prices were between $11.15 and $24.64, with an estimated average price of $18.62. The stock is now traded at around $24.12. The impact to a portfolio due to this purchase was 0.18%. The holding were 1,500,000 shares as of .

Farallon Capital Management Llc added to a holding in Protagonist Therapeutics Inc by 66.67%. The purchase prices were between $6.19 and $18.84, with an estimated average price of $12.43. The stock is now traded at around $18.22. The impact to a portfolio due to this purchase was 0.16%. The holding were 2,500,000 shares as of .

Farallon Capital Management Llc sold out a holding in IAC/InterActiveCorp. The sale prices were between $51.95 and $100.12, with an estimated average price of $76.44.

Farallon Capital Management Llc sold out a holding in Forty Seven Inc. The sale prices were between $95.42 and $95.51, with an estimated average price of $95.46.

Farallon Capital Management Llc sold out a holding in Ra Pharmaceuticals Inc. The sale prices were between $48 and $48.01, with an estimated average price of $48.

Farallon Capital Management Llc sold out a holding in Progenics Pharmaceuticals Inc. The sale prices were between $3 and $4.8, with an estimated average price of $3.96.

Farallon Capital Management Llc sold out a holding in Momenta Pharmaceuticals Inc. The sale prices were between $24.19 and $39.27, with an estimated average price of $31.75.

Farallon Capital Management Llc sold out a holding in Atara Biotherapeutics Inc. The sale prices were between $7.53 and $14.93, with an estimated average price of $10.13.